Stock Track | Illumina Plunges 5.68% Pre-market on Lower 2025 Outlook, China Risks

Stock Track

Feb 07, 2025

Shares of gene sequencing equipment maker Illumina (ILMN) plunged 5.68% in pre-market trading on Friday, following the company's lower than expected revenue forecast for 2025 and geopolitical risks arising from China placing it on an "unreliable entity" list.

For 2025, Illumina expects revenue in the range of $4.28 billion to $4.40 billion, falling short of Wall Street's average estimate of around $4.39 billion. The company cited macroeconomic headwinds and competitive pressures impacting instrument sales as reasons for the muted outlook.

Adding to the concerns, China, which accounts for around 7% of Illumina's sales, put the company on an "unreliable entity" list earlier this week. While Illumina said its 2025 guidance does not reflect any potential impact from this move, analysts view it as a significant risk given the company's exposure to the Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1133159925"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133159925\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133159925?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133159925","market":"us","top_or_hot":-1,"title":"Stock Track | Illumina Plunges 5.68% Pre-market on Lower 2025 Outlook, China Risks","media":"Stock Track","content":"<p>Shares of gene sequencing equipment maker Illumina (ILMN) plunged 5.68% in pre-market trading on Friday, following the company's lower than expected revenue forecast for 2025 and geopolitical risks arising from China placing it on an \"unreliable entity\" list.</p>\n\n<p>For 2025, Illumina expects revenue in the range of $4.28 billion to $4.40 billion, falling short of Wall Street's average estimate of around $4.39 billion. The company cited macroeconomic headwinds and competitive pressures impacting instrument sales as reasons for the muted outlook.</p>\n\n<p>Adding to the concerns, China, which accounts for around 7% of Illumina's sales, put the company on an \"unreliable entity\" list earlier this week. While Illumina said its 2025 guidance does not reflect any potential impact from this move, analysts view it as a significant risk given the company's exposure to the Chinese market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Illumina Plunges 5.68% Pre-market on Lower 2025 Outlook, China Risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Illumina Plunges 5.68% Pre-market on Lower 2025 Outlook, China Risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-07 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of gene sequencing equipment maker Illumina (ILMN) plunged 5.68% in pre-market trading on Friday, following the company's lower than expected revenue forecast for 2025 and geopolitical risks arising from China placing it on an \"unreliable entity\" list.</p>\n\n<p>For 2025, Illumina expects revenue in the range of $4.28 billion to $4.40 billion, falling short of Wall Street's average estimate of around $4.39 billion. The company cited macroeconomic headwinds and competitive pressures impacting instrument sales as reasons for the muted outlook.</p>\n\n<p>Adding to the concerns, China, which accounts for around 7% of Illumina's sales, put the company on an \"unreliable entity\" list earlier this week. While Illumina said its 2025 guidance does not reflect any potential impact from this move, analysts view it as a significant risk given the company's exposure to the Chinese market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1133159925","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133159925","pubTimestamp":1738931907,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of gene sequencing equipment maker Illumina  plunged 5.68% in pre-market trading on Friday, following the company's lower than expected revenue forecast for 2025 and geopolitical risks arising from China placing it on an \"unreliable entity\" list.For 2025, Illumina expects revenue in the range of $4.28 billion to $4.40 billion, falling short of Wall Street's average estimate of around $4.39 billion. The company cited macroeconomic headwinds and competitive pressures impacting instrument sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"股票赛道Illumina因2025年前景下调和中国风险而盘前暴跌5.68%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"Shares of gene sequencing equipment maker Illumina (ILMN) plunged 5.68% in pre-market trading on Friday, following the company's lower than expected revenue forecast for 2025 and geopolitical risks arising from China placing it on an \"unreliable entity\" list.\nFor 2025, Illumina expects revenue in the range of $4.28 billion to $4.40 billion, falling short of Wall Street's average estimate of around $4.39 billion. The company cited macroeconomic headwinds and competitive pressures impacting instrument sales as reasons for the muted outlook.\nAdding to the concerns, China, which accounts for around 7% of Illumina's sales, put the company on an \"unreliable entity\" list earlier this week. While Illumina said its 2025 guidance does not reflect any potential impact from this move, analysts view it as a significant risk given the company's exposure to the Chinese market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}